Changes in serum HDL and LDL cholesterol in patients with paget’s bone disease treated with pamidronate

• Published in: Bone (New York, N.Y.) Vol. 32; no. 1; pp. 15 - 19
• Main Authors: Montagnani, A, Gonnelli, S, Cepollaro, C, Campagna, M.S, Franci, M.B, Pacini, S, Gennari, C
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 2003; Elsevier Science
• Subjects: Aged; Analysis of Variance; Biological and medical sciences; Cholesterol; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Diphosphonates - therapeutic use; Diseases of the osteoarticular system; Female; Fundamental and applied biological sciences. Psychology; Humans; Infusions, Intravenous; Lipoproteins; Male; Medical sciences; Middle Aged; Osteitis Deformans - blood; Osteitis Deformans - drug therapy; Osteoporosis. Osteomalacia. Paget disease; Paget; Pamidronate; Traumas. Diseases due to physical agents; Vertebrates: anatomy and physiology, studies on body, several organs or systems; Paget; Pamidronate; Lipoproteins; Cholesterol; Human; Paget disease; Diseases of the osteoarticular system; Bone disease; Lipoprotein; Pamidronic acid; Treatment; Morphology; Orthopedics; Serum; Physiology
• ISSN: 8756-3282; 1873-2763
• DOI: 10.1016/S8756-3282(02)00924-9

Amino bisphosphonates represent one of the most important advances in the management of Paget’s and other metabolic bone diseases. Although their mechanism of action has not yet been completely clarified, they seem to inhibit the mevalonate pathway and so they could interfere with cholesterol synthesis. The present study aimed to evaluate cholesterol and lipoprotein serum levels in patients with Paget’s bone disease treated with intravenous pamidronate. The study included 20 consecutive patients (mean age, 67.6 ± 11.0 years) with Paget’s bone disease for at least 1 year, who needed intravenous amino bisphosphonate treatment; 12 patients with inactive Paget’s bone disease served as controls. The patients with active Paget’s bone disease underwent three cycles (every 3 months) of treatment with 60 mg of intravenous pamidronate. Controls were given a saline infusion following the same administration schedule. In all subjects total alkaline phosphatase (total ALP), bone alkaline phosphatase (bone ALP), total cholesterol (TC), tryglycerides (TG), and high- and low-density lipoprotein cholesterol (HDL-C and LDL-C, respectively) were measured before infusions (pamidronate or saline) at baseline and at 3-month intervals up to 9 months. In the control group no significant changes were observed through the study period for any of the biochemical parameters. In the pamidronate-treated patients, both bone ALP and total ALP significantly fell at the end of the study. In patients with active treatment, at the end of the study period HDL-C significantly ( P < 0.05) increased by 10.3%, whereas LDL-C significantly ( P < 0.05) decreased by 5.5%. In these patients TC showed a negative trend without reaching statistical significance, whereas the HDL-C/LDL-C ratio rose 16.2% above the basal value and TC/HDL-C decreased by 12.5%. In conclusion, pamidronate given intravenously seems to be able to induce a prolonged shifting in circulating cholesterol from the LDL-C to the HDL-C from associated with a weak decrease in total cholesterol, thus producing a possible improvement in the atherosclerotic risk index.